| Name | Nemifitide diTFA |
| Description | Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide that can cross the blood-brain barrier and acts as a potent antidepressant, similar to melanocyte suppressor factor (MIF). |
| In vitro | Nemifitide diTFA (INN 00835 diTFA) and its active metabolite (M1) bind to multiple receptors, including 5-HT2A, 5-HT2C, melanocortin MC4, MC5, and bombesin, at micromolar concentrations[2]. |
| In vivo | Administered intraperitoneally at a dose of 0.3 mg/kg daily for 14 days, Nemifitide diTFA (INN 00835 diTFA) significantly increases swimming behavior in the FSL rats after just 5 days of treatment, and this effect has a long-lasting duration[2]. Moreover, across a range of doses (0.0125-15.0 mg/kg), Nemifitide diTFA demonstrates a significant increase in swimming behavior in FSL rats at both low (0.025-0.3 mg/kg) and high (3.0-15.0 mg/kg) doses, but not at intermediate (0.4-2.4 mg/kg) doses[3]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 200 mg/mL (216.73 mM), Sonication is recommended.
|
| Keywords | Nemifitide diTFA | Nemifitide | INN-00835 | INN00835 | INN 00835 | 5HTReceptor | 5HT Receptor | 5-HT |
| Inhibitors Related | Alverine citrate | Sevoflurane | Dapoxetine hydrochloride | Cefaclor monohydrate | Clozapine N-Oxide | 1,8-Cineole | Dopamine hydrochloride | Cloperastine hydrochloride | Mianserin hydrochloride | Trazodone hydrochloride | Cinchonidine | Doxepin hydrochloride |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Peptide Compound Library | Drug Repurposing Compound Library | CNS-Penetrant Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |